Case number 1:22-cv-00451
Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Mar 6, 2024 | 127 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,058,667 B2. (Attachments: # 1 Order)(nms) (Entered: 03/06/2024) (0) |
| Mar 5, 2024 | 126 | REDACTED VERSION of 124 Stipulation of Dismissal, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 3/6/2024 (nms). (Entered: 03/05/2024) (4) |
| Feb 27, 2024 | 124 | [SEALED] STIPULATION of Dismissal by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 02/27/2024) (0) |
| Feb 27, 2024 | 125 | [SEALED] ORDER Granting (D.I. 124 in 22-cv-451-RGA; D.I. 1283 in 20-md-2930-RGA; D.I. 150 in 22-cv-1395-RGA) Stipulation and Order of Dismissal between Plaintiff and Defendant Mylan Pharmaceuticals Inc.. Signed by Judge Richard G. Andrews on 2/27/2024.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-00451-RGA, 1:22-cv-01395-RGA(nms) (Entered: 02/27/2024) (0) |
| Jan 30, 2024 | 123 | REDACTED VERSION of 121 Sealed Stipulation, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 1/31/2024 (nms). (Entered: 01/30/2024) (5) |
| Jan 23, 2024 | 121 | [SEALED] STIPULATION and [Proposed] Order Staying Mylan Actions by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 01/23/2024) (0) |
| Jan 23, 2024 | 122 | [SEALED] SO ORDERED Granting (D.I. 136 in 22-cv-1395-RGA; D.I. 1238 in 20-md-2930-RGA; D.I. 121 in 22-cv-451-RGA) Stipulation and Proposed Order Staying Mylan Actions. Signed by Judge Richard G. Andrews on 1/23/2024.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-00451-RGA, 1:22-cv-01395-RGA(nms) (Entered: 01/23/2024) (0) |
| Dec 18, 2023 | 120 | Joint letter to The Honorable Richard G. Andrews, from Daniel A. Taylor, regarding trials for the '667 & '918 patents. (Taylor, Daniel) Modified on 12/19/2023 (nms). (Entered: 12/18/2023) (3) |
| Nov 20, 2023 | 119 | NOTICE OF SERVICE of Sur-Reply Expert Report of Stuart D. Katz Regarding Validity of U.S. Patent No. 11,058,667 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 11/20/2023) (4) |
| Nov 6, 2023 | 117 | NOTICE OF SERVICE of Reply Expert Report of Dan Fintel, M.D. on The Invalidity of U.S. Patent No. 11,058,667 [Highly Confidential - Outside Attorneys' Eyes Only] (also filed on behalf of the Hetero and Torrent Defendants) filed by Mylan Pharmaceuticals Inc..(Palapura, Bindu) (Entered: 11/06/2023) (3) |
| Nov 6, 2023 | 118 | NOTICE OF SERVICE of (1) Reply Expert Report of Adam J. Matzger, Ph.D. on Infringement of U.S. Patent No. 11,058,667 by Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III, Mylan Pharmaceuticals Inc., Torrent Pharma Inc., and Torrent Pharmaceuticals Ltd., (2) Reply Expert Report of Alexander M. Klibanov, Ph.D., on the Infringement of the '667 Patent, and (3) Reply Expert Report of Dr. Francis G. Spinale on the Infringement of the '667 Patent filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 11/06/2023) (4) |
| Oct 25, 2023 | 116 | NOTICE OF SERVICE of Novartis's Objections and Responses to Defendants' Supplemental Notice of Deposition to Plaintiff Novartis Pharmaceuticals Corporation Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 10/25/2023) (4) |
| Oct 19, 2023 | 114 | NOTICE to Take Deposition of Nicole Twisk filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd..(Taylor, Daniel) (Entered: 10/19/2023) (3) |
| Oct 19, 2023 | 115 | NOTICE to Take Deposition of Novartis Pharmaceuticals Corporation Pursuant to Rule 30(b)(6) filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd..(Taylor, Daniel) (Entered: 10/19/2023) (4) |
| Sep 29, 2023 | 112 | REDACTED VERSION of 107 Letter, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 10/2/2023 (nms). (Entered: 09/29/2023) (30) |
| Sep 29, 2023 | 113 | REDACTED VERSION of 110 Letter, by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd.. (Attachments: # 1 Exhibits 1-10)(Taylor, Daniel) Modified on 10/2/2023 (nms). (Entered: 09/29/2023) (0) |
| Sep 25, 2023 | 111 | STIPULATION and Proposed Order to Extend Time - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 9/26/2023 (nms). (Entered: 09/25/2023) (4) |
| Sep 20, 2023 | 110 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel A. Taylor, regarding response in opposition to Plaintiff's motion to strike. (Attachments: # 1 Exhibits 1-10, # 2 Proposed Order, # 3 Certificate of Service)(Taylor, Daniel) Modified on 9/21/2023 (nms). (Entered: 09/20/2023) (0) |
| Sep 19, 2023 | 108 | NOTICE OF SERVICE of Novartis's Objections and Responses to Defendants' 2nd Set of Requests for Admission to Plaintiff Novartis Pharmaceuticals Corp. to Establish the Authenticity of Documents or to Establish Documents as Business Records filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 09/19/2023) (4) |
| Sep 19, 2023 | 109 | ORAL ORDER: Due to a scheduling conflict the Discovery Conference set for 9/27/2023, will now commence at 2:30 PM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 9/19/2023. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01760-RGA, 1:21-cv-01794-RGA, 1:22-cv-00451-RGA(nms) (Entered: 09/19/2023) (0) |
| Sep 18, 2023 | 107 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding opening expert report. (Attachments: # 1 Exhibits A-K, # 2 Proposed Order, # 3 Certificate of Service)(Silver, Daniel) Modified on 9/19/2023 (nms). (Entered: 09/18/2023) (0) |
| Sep 11, 2023 | 104 | NOTICE OF SERVICE of Expert Report of Stuart D. Katz Regarding Validity of U.S. Patent No. 11,058,667 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 09/11/2023) (4) |
| Sep 11, 2023 | 105 | NOTICE OF SERVICE of Defendants Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III, Mylan Pharmaceuticals Inc., Torrent Pharma Inc., and Torrent Pharmaceuticals Limited's Highly Confidential Responsive Expert Report of Dan Fintel, M.D. on noninfringement the '667 patent filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd..(Taylor, Daniel) (Entered: 09/11/2023) (2) |
| Sep 11, 2023 | 106 | NOTICE OF SERVICE of Defendants Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III, Mylan Pharmaceuticals Inc., Torrent Pharma Inc., and Torrent Pharmaceuticals Limited's Highly Confidential Responsive Expert Report of Jonathan W. Steed, Ph.D. on non-infringement of the '667 patent filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd..(Taylor, Daniel) (Entered: 09/11/2023) (2) |
| Aug 30, 2023 | 103 | ORAL ORDER: The parties have advised that a dispute has arisen requiring attention. The Court will hold a discovery conference on 9/27/2023, at 9:00 AM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Ordered by Judge Richard G. Andrews on 8/30/2023. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01760-RGA, 1:21-cv-01794-RGA, 1:22-cv-00451-RGA(nms) (Entered: 08/30/2023) (0) |
| Aug 18, 2023 | 102 | NOTICE OF SERVICE of Defendants Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III, Mylan Pharmaceuticals, Inc., Torrent Pharma Inc., and Torrent Pharmaceuticals Ltd.'s 2nd Set of Requests for Admissions (Nos. 1-5) to Plaintiff Novartis Pharmaceuticals Corporation to establish the authenticity of documents or establish documents as business records, regarding U.S. Patent No. 11,058,667 ("the '667 patent") filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd..(Belgam, Neal) (Entered: 08/18/2023) (2) |
| Jul 31, 2023 | 99 | NOTICE OF SERVICE of (1) Expert Report of Dr. Francis G. Spinale on the Infringement of the 667 Patent and (2) Opening Expert Report of Dr. Alexander M. Klibanov on the Infringement of the 667 Patent filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 07/31/2023) (5) |
| Jul 31, 2023 | 100 | NOTICE OF SERVICE of Novartis's Objections and Responses to Defendants' Requests for Admission to Plaintiff Novartis Pharmaceuticals Corporation to Establish the Authenticity of Documents or to Establish Documents as Business Records filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 07/31/2023) (4) |
| Jul 31, 2023 | 101 | NOTICE OF SERVICE of Opening Expert Report of Dan Fintel, M.D. on the Invalidity of U.S. Patent No. 11,058,667 [Highly Confidential-Outside Attorneys' Eyes Only] (also filed on behalf of the Hetero and Torrent Defendants) filed by Mylan Pharmaceuticals Inc..(Brown, Andrew) (Entered: 07/31/2023) (3) |
| Jul 12, 2023 | 98 | STIPULATION and Proposed Order to Extend Time regarding expert reports - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 7/12/2023 (nms). (Entered: 07/12/2023) (4) |
| Jul 7, 2023 | 97 | REDACTED VERSION of 95 Stipulation and Proposed Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/7/2023 (nms). (Entered: 07/07/2023) (6) |
| Jun 30, 2023 | 95 | [SEALED] STIPULATION and [Proposed] Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/30/2023 (nms). (Entered: 06/30/2023) (0) |
| Jun 30, 2023 | 96 | [SEALED] ORDER Granting (16 in 23-cv-401-RGA; 82 in 22-cv-1395-RGA; 176 in 21-cv-1330-RGA; 1091 in 20-md-2930-RGA; 95 in 22-cv-451-RGA) Stipulation and Proposed Order. Signed by Judge Richard G. Andrews on 6/30/2023.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:22-cv-00451-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 06/30/2023) (0) |
| Jun 29, 2023 | 94 | MOTION for Pro Hac Vice Appearance of Attorney Melinda R. Roberts - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification for Melinda R. Roberts)(Silver, Daniel) (Entered: 06/29/2023) (Main Document) (4) |
| Jun 29, 2023 | 94 | MOTION for Pro Hac Vice Appearance of Attorney Melinda R. Roberts - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification for Melinda R. Roberts)(Silver, Daniel) (Entered: 06/29/2023) (Certification for Melinda R. Roberts) (1) |
| Jun 28, 2023 | 93 | NOTICE OF SERVICE of Defendants Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III, Mylan Pharmaceuticals, Inc., Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Requests for Admissions to Establish the Authenticity of Documents or Establish Documents as Business Records to Plaintiff Novartis Pharmaceuticals Corporation filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd..(Taylor, Daniel) (Entered: 06/28/2023) (2) |
| Jun 21, 2023 | 92 | NOTICE to Take Deposition of Nicole Twisk on June 30, 2023 filed by Mylan Pharmaceuticals Inc..(Palapura, Bindu) (Entered: 06/21/2023) (3) |
| Jun 20, 2023 | 91 | NOTICE to Take Deposition of Michael Motto on June 29, 2023 filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd..(Taylor, Daniel) (Entered: 06/20/2023) (3) |
| Jun 16, 2023 | 90 | NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendants' Third Set of Common Interrogatories (No. 14), and (2) Novartis's Second Supplemental Objections and Responses to Defendants' First Set of Common Interrogatories (Nos. 1-9) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/16/2023) (4) |
| Jun 15, 2023 | 89 | NOTICE OF SERVICE of Responses And Objections To Novartis's Third Set Of Interrogatories To Mylan Pharmaceuticals Inc. (Nos. 5 & 6) [Highly Confidential Attorneys' Eyes Only], Supplemental Responses And Objections To Novartis's First Set Of Interrogatories To Mylan Pharmaceuticals Inc. (Nos. 1-3) [Highly Confidential Attorneys' Eyes Only], and Supplemental Responses And Objections To Novartis's Second Set Of Interrogatories To Mylan Pharmaceuticals Inc. (Nos. 4-5) [Highly Confidential Attorneys' Eyes Only] filed by Mylan Pharmaceuticals Inc..(Palapura, Bindu) (Entered: 06/15/2023) (2) |
| Jun 14, 2023 | 87 | NOTICE to Take Deposition of Adel Remond Rizkala on June 16, 2023, filed by Mylan Pharmaceuticals Inc..(Moore, David) Modified on 6/14/2023 (nms). (Entered: 06/14/2023) (3) |
| Jun 14, 2023 | 88 | NOTICE to Take Deposition of Nicole Twisk, filed by Mylan Pharmaceuticals Inc..(Moore, David) Modified on 6/14/2023 (nms). (Entered: 06/14/2023) (3) |
| Jun 13, 2023 | 86 | NOTICE OF SERVICE of (1) Plaintiff's Supplemental Initial Paragraph 3 Disclosures Regarding Electronic Systems Information regarding the '667 Patent and (2) Plaintiff's Supplemental Rule 26 (A)(1) Initial Disclosures regarding the '667 Patent filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/13/2023) (4) |
| Jun 8, 2023 | 85 | NOTICE OF SERVICE of Mylan Pharmaceuticals Inc.'s Responses And Objections To Novartis's Requests For Admissions To Mylan Pharmaceuticals Inc. To Establish The Authenticity Of Documents Or Establish Documents As Business Records; and Mylan Pharmaceuticals Inc.'s Responses And Objections To Novartis's Notice Of Deposition Under Fed. R. Civ. P. 30(b)(6) To Mylan Pharmaceuticals Inc. filed by Mylan Pharmaceuticals Inc..(Brown, Andrew) (Entered: 06/08/2023) (2) |
| Jun 5, 2023 | 84 | NOTICE to Take Deposition of Peter Waibel on June 14, 2023 filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd..(Taylor, Daniel) (Entered: 06/05/2023) (3) |
| May 30, 2023 | 82 | NOTICE OF SERVICE of Responses and Objections to Novartis's Second Set of Common Interrogatories to Defendants filed by Mylan Pharmaceuticals Inc..(Brown, Andrew) (Entered: 05/30/2023) (3) |
| May 30, 2023 | 83 | NOTICE OF SERVICE of Mylan Pharmaceuticals Inc.'s Responses And Objections To Novartis's First Set Of Requests For Admission To Mylan Pharmaceuticals Inc. [Highly Confidential Attorneys' Eyes Only] filed by Mylan Pharmaceuticals Inc..(Brown, Andrew) (Entered: 05/30/2023) (2) |
| May 22, 2023 | 81 | NOTICE OF SERVICE of Novartis Objections and Responses to Defendants' Notice of Deposition to Plaintiff Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/22/2023) (5) |
| May 19, 2023 | 80 | NOTICE OF SERVICE of Defendants' Joint Supplemental Invalidity Contentions for U.S. Patent No. 11,058,667 filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 05/19/2023) (3) |
| May 17, 2023 | 77 | NOTICE OF SERVICE of (1) Novartis's First Supplemental Objections and Responses to Defendants' First Set of Common Interrogatories (Nos. 1-9), (2) Novartis's Third Set of Interrogatories to Defendants (Nos. 5 & 6), and (3) Plaintiff Novartis's Supplemental Infringement Contentions Against Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/17/2023) (6) |
| May 17, 2023 | 78 | NOTICE OF SERVICE of Defendants' Third Set of Common Interrogatories (667 Patent) to Novartis (No. 14) filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 05/17/2023) (3) |
| May 17, 2023 | 79 | MOTION for Pro Hac Vice Appearance of Attorney Melanie Black Dubis of Parker Poe Adams & Bernstein LLP - filed by Mylan Pharmaceuticals Inc.. (Moore, David) (Entered: 05/17/2023) (3) |
| May 11, 2023 | 76 | NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendants' Second Set of Common Interrogatories (Nos. 10-13), (2) Novartis's Objections and Responses to Defendants' Second Set of Joint Requests for the Production of Documents and Things (Nos. 45-56), (3) Novartis's Supplemental Infringement Contentions Against Crystal Pharmaceutical (Suzhou) Co., Ltd., and (4) Novartis's Objections and Responses to Crystal's First Set of Individual Interrogatories (Nos. 1-3) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/11/2023) (6) |
| May 9, 2023 | 74 | NOTICE of Deposition Under Fed. R. Civ. P. 30(B)(6) to Mylan Pharmaceuticals Inc. by Novartis Pharmaceuticals Corporation (Joyce, Alexandra) (Entered: 05/09/2023) (5) |
| May 9, 2023 | 75 | NOTICE OF SERVICE of Novartis's Requests for Admissions to Defendants to Establish the Authenticity of Documents or Establish Documents as Business Records filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/09/2023) (6) |
| May 5, 2023 | 69 | NOTICE to Take Deposition of Adel Remond Rizkala on at a date, time, and/or location to be determined filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 05/05/2023) (4) |
| May 5, 2023 | 70 | NOTICE to Take Deposition of Marcia Kayath on date, time, and/or location to be determined filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 05/05/2023) (4) |
| May 5, 2023 | 71 | NOTICE to Take Deposition of Victor Chengwei Shi on date, time, and/or location to be determined filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 05/05/2023) (4) |
| May 5, 2023 | 72 | NOTICE to Take Deposition of Fabian Chen on date, time, and/or location to be determined filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 05/05/2023) (4) |
| May 5, 2023 | 73 | NOTICE to Take Deposition of Plaintiff Novartis Pharmaceuticals Corporation on date, time, and/or location to be determined filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 05/05/2023) (12) |
| Apr 26, 2023 | 68 | NOTICE OF SERVICE of (1) Novartis's Second Set of Common Interrogatories to Defendants and (2) Novartis's First Set of Requests for Admissions to Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 04/26/2023) (6) |
| Apr 12, 2023 | 67 | ORAL ORDER: The agreed-upon constructius (see D.I. 66 in 22-cv-451-RGA; D.I. 56 in 21-cv-1452-RGA; D.I. 58 in 22-cv-498-RGA; D.I. 989 in 20-md-2930-RGA; D.I. 56 in 21-cv-1760-RGA; D.I. 55 in 21-cv-1794-RGA) are ACCEPTED. The Markman hearing scheduled for 4/14/2023, is CANCELED. Ordered by Judge Richard G. Andrews on 4/12/2023. Associated Cases: 1:20-md-02930-RGA et al.(nms) (Entered: 04/12/2023) (0) |
| Apr 11, 2023 | 65 | NOTICE OF SERVICE of copies of (i) Defendants' Second Set of Common Interrogatories to Novartis (Nos. 10-13); and, (ii) Defendants' Second Set of Joint Requests for the Production of Documents and Things (Nos. 45-56) to Novartis filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 04/11/2023) (3) |
| Apr 11, 2023 | 66 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding Markman hearing scheduled for 4/14/2023, regarding U.S. Patent No. 11,058,667. (Silver, Daniel) Modified on 4/12/2023 (nms). (Entered: 04/11/2023) (2) |
| Apr 7, 2023 | 64 | REDACTED VERSION of 60 Appendix, Volume 2, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 4/7/2023 (nms). (Entered: 04/07/2023) (20) |
| Apr 5, 2023 | 63 | MARKMAN HEARING ORDER: The Joint Claim Construction Brief (D.I. 974 ) is UNSEALED. The argument at the Markman Hearing on April 14, 2023, is limited to ten minutes per side. For the first disputed term, there appears to be a definition at '667 Patent 16:20-24. I think that is what each side means by their proposals. In any event, the parties' proposals are STRUCK. If either party thinks the above-referenced definition is inadequate in some regard, that party is to propose a construction including the definition and any additional language that the party argues is necessary. "Specific," as already proposed by Defendants, is rejected. I note that "crystalline," as proposed by Defendants, seems to be agreed upon by Novartis. (D.I. 974 at 31). But I am unclear whether it is necessary. Any proposed constructions should be submitted by 5 p.m. Tuesday, April 11, 2023. The proposed construction and any justification for it shall be set forth in 250 words or less. For the second disputed term, there also appears to be a definition, this time at '667 Patent 5:22-35. The parties only have one disagreement (in addition to the one addressed above in 3), which is Defendants' proposed negative limitation. As I understand Novartis's position, there is no dispute because part (a) of the definition includes exactly one "complex"-the one described at '667 Patent 16:20-24-and part (b) includes no complexes at all. If Novartis confirms that I understand its position correctly, then I also agree with Novartis that adding a negative limitation is pointless. Novartis should advise whether it confirms the above no later than 5 p.m. Tuesday, April 11, 2023. Signed by Judge Richard G. Andrews on 4/5/2023. Associated Cases: 1:20-md-02930-RGA et al.(nms) (Entered: 04/05/2023) (2) |
| Mar 31, 2023 | 58 | Joint Claim Construction Brief regarding U.S. Patent No. 11,058,667, filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 3/31/2023 (nms). Modified on 4/5/2023 (nms). (Entered: 03/31/2023) (30) |
| Mar 31, 2023 | 59 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Main Document) (5) |
| Mar 31, 2023 | 60 | [SEALED] APPENDIX, Volume 2 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits L-N)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (0) |
| Mar 31, 2023 | 61 | APPENDIX, Volume 3 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits O-V)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Main Document) (5) |
| Mar 31, 2023 | 62 | Joint Motion for Claim Construction - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 4/3/2023 (nms). (Entered: 03/31/2023) (8) |
| Mar 31, 2023 | 59 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 1) (16) |
| Mar 31, 2023 | 59 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 2 Pt. 1 of 5) (30) |
| Mar 31, 2023 | 59 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 2 Pt. 2 of 5) (30) |
| Mar 31, 2023 | 59 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 2 Pt. 3 of 5) (30) |
| Mar 31, 2023 | 59 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 2 Pt. 4 of 5) (30) |
| Mar 31, 2023 | 59 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 2 Pt. 5 of 5) (13) |
| Mar 31, 2023 | 59 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit A-K) (30) |
| Mar 31, 2023 | 61 | APPENDIX, Volume 3 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits O-V)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit O-V) (30) |
| Mar 24, 2023 | 57 | NOTICE OF SERVICE of (i) Defendants' Sur-Reply Brief on Claim Construction for U.S. Patent No. 11,058,667 with Exs. U and V [HIGHLY CONFIDENTIAL-ATTORNEYS EYES ONLY]; and, (ii) a replacement version of Ex. H, which was previously served on February 10, 2023 with Defendants' Responsive Brief on Claim Construction for U.S. Patent No. 11,058,667 filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 03/24/2023) (3) |
| Mar 22, 2023 | 56 | NOTICE of Change of Address by Alexandra M. Joyce (Joyce, Alexandra) (Entered: 03/22/2023) (5) |
| Mar 6, 2023 | 54 | NOTICE OF SERVICE of Defendants' Objections and Responses to Novartis's First Set of Common Interrogatories (No. 1) filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 03/06/2023) (5) |
| Mar 6, 2023 | 55 | NOTICE OF SERVICE of Novartis's Reply Brief on Claim Construction for U.S. Patent No. 11,058,667 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 03/06/2023) (7) |
| Feb 10, 2023 | 53 | NOTICE OF SERVICE of Defendants' Responsive Brief on Claim Construction for U.S. Patent No. 11,058,667 [HIGHLY CONFIDENTIAL] filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 02/10/2023) (3) |
| Feb 2, 2023 | 52 | NOTICE OF SERVICE of Novartis's First Set of Common Interrogatories to Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 02/02/2023) (7) |
| Jan 23, 2023 | 51 | NOTICE OF SERVICE of Novartis's Opening Brief on Claim Construction for U.S. Patent No. 11,058,667 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 01/23/2023) (7) |
| Dec 30, 2022 | 50 | JOINT Claim Construction Chart for U.S. Patent No. 11,058,667, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Appendix)(Silver, Daniel) Modified on 1/2/2023 (nms). (Entered: 12/30/2022) (Main Document) (13) |
| Dec 30, 2022 | 50 | JOINT Claim Construction Chart for U.S. Patent No. 11,058,667, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Appendix)(Silver, Daniel) Modified on 1/2/2023 (nms). (Entered: 12/30/2022) (Appendix) (30) |
| Dec 15, 2022 | 48 | NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendants' First Set of Joint Requests for Production (Nos. 1-44) for the '667 patent, and (2) Novartis's Objections and Responses to Defendants' First Set of Common Interrogatories (Nos. 1-9) for the '667 patent filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 12/15/2022) (7) |
| Dec 15, 2022 | 49 | NOTICE OF SERVICE of Novartis's Rebuttal Proposed Constructions of Claim Terms and Evidence for U.S. Patent No. 11,058,667 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 12/15/2022) (7) |
| Dec 6, 2022 | 47 | STIPULATION TO EXTEND TIME the Deadline to Substantially Complete Document Production to January 18, 2023 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 12/06/2022) (7) |
| Nov 8, 2022 | 46 | NOTICE OF SERVICE of Responses and Objections to Novartis's Second Set of Interrogatories to Mylan Pharmaceuticals Inc. (Nos. 4-5) [Highly Confidential] filed by Mylan Pharmaceuticals Inc..(Palapura, Bindu) (Entered: 11/08/2022) (2) |
| Oct 7, 2022 | 45 | NOTICE OF SERVICE of Novartis's Second Set of Interrogatories to Defendants filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 10/07/2022) (10) |
| Sep 9, 2022 | 44 | NOTICE OF SERVICE of Mylan Pharmaceuticals Inc.'s Responses And Objections To Novartis's First Set Of Interrogatories To Mylan Pharmaceuticals Inc. (Nos. 1-3) [Highly Confidential Attorneys' Eyes Only]; and Mylan Pharmaceuticals Inc.'s Responses And Objections To Novartis's First Set Of Requests To Mylan Pharmaceuticals Inc. For The Production Of Documents And Things [Highly Confidential Attorneys' Eyes Only] filed by Mylan Pharmaceuticals Inc..(Moore, David) (Entered: 09/09/2022) (2) |
| Sep 7, 2022 | 43 | NOTICE OF SERVICE of (1) Plaintiff's Rule 26(a)(1) Initial Disclosures, and (2) Plaintiff's Initial Paragraph 3 Disclosures Regarding Electronic Systems Information filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 09/07/2022) (14) |
| Aug 29, 2022 | 42 | SCHEDULING ORDER: Joinder of Parties due by 1/5/2023. Amended Pleadings due by 1/5/2023. Fact Discovery completed by 6/16/2023. Joint Claim Construction Brief due by 3/31/2023. A Markman Hearing is set for 4/14/2023, at 9:00 AM in Courtroom 6A. A Pretrial Conference is set for 2/2/2024, at 9:00 AM in Courtroom 6A. A 7 day Bench Trial is set to start 2/12/2024, at 8:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 8/29/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) (Entered: 08/29/2022) (21) |
| Aug 26, 2022 | 41 | PROPOSED Scheduling Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/28/2022 (nms). (Entered: 08/26/2022) (21) |
| Aug 17, 2022 | 40 | Official Transcript of Rule 16 Conference held on 8/3/22 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 9/7/2022. Redacted Transcript Deadline set for 9/19/2022. Release of Transcript Restriction set for 11/15/2022. (Triozzi, Heather) (Entered: 08/17/2022) (29) |
| Aug 11, 2022 | 39 | NOTICE OF SERVICE of (1) Novartis's First Set of Requests to Defendants for the Production of Documents and Things and (2) Novartis's First Set of Interrogatories to Defendants (Nos. 1-3) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 08/11/2022) (13) |
| Aug 3, 2022 | N/A | Scheduling Conference (0) Docket Text: Minute Entry for proceedings held before Judge Richard G. Andrews - Scheduling Conference held on 8/3/2022. Counsel for Plaintiff: D. Silver. Counsel for Defendants: E. Ormerod, A. Poff, R. Weinblatt, C. Hitch, D. Gattuso, B. Palapura, J. Seaman. Plaintiff is directed to submit the revised order. (Court Reporter Heather Triozzi.) Associated Cases: 1:22-cv-00032-RGA et al.(lak) |
| Jul 25, 2022 | 38 | Notice of Service (16) Docket Text: NOTICE OF SERVICE of Plaintiff's Initial Infringement Chart for U.S. Patent No. 11,058,667 and Plaintiff's First Supplemental Infringement Chart for U.S. Patent No. 11,096,918 against Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Jul 21, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: A Scheduling Conference is now set for 8/3/2022, at 2:00 PM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 7/21/2022. Associated Cases: 1:22-cv-00032-RGA et al.(nms) |
| Jun 15, 2022 | 36 | Proposed Order (21) Docket Text: PROPOSED Scheduling Order (with disputed provisions), by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/15/2022 (nms). |
| Jun 13, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order Extending Time to submit a Proposed Scheduling Order to June 15, 2022. Signed by Judge Richard G. Andrews on 6/13/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Jun 10, 2022 | 35 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION and Proposed Order Extending Time to submit Proposed Scheduling Order to June 15, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/13/2022 (nms). |
| Jun 9, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order to June 10, 2022. Signed by Judge Richard G. Andrews on 6/9/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Jun 9, 2022 | 34 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for parties to submit a Proposed Scheduling Order to June 10, 2022 - filed by Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd.. (Ormerod, Eve) |
| Jun 2, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to June 8, 2022. Signed by Judge Richard G. Andrews on 6/2/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Jun 1, 2022 | 32 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME the parties' deadline to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 in accordance with the Court's oral order at the April 21, 2022 status conference to June 8, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| May 26, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to and including June 1, 2022. Signed by Judge Richard G. Andrews on 5/26/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 25, 2022 | 31 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for the parties to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 in accordance with the Court's oral order at the April 21, 2022 status conference to June 1, 2022 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 19, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to May 25, 2022. Signed by Judge Richard G. Andrews on 5/19/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 18, 2022 | 30 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME deadline to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to May 25, 2022. - filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) |
| May 11, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order to May 18, 2022. Signed by Judge Richard G. Andrews on 5/11/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 11, 2022 | 29 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for parties to submit a Proposed Scheduling Order to May 18, 2022 - filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Hetero USA Inc.,, Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Ormerod, Eve) |
| May 5, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to May 11, 2022. Signed by Judge Richard G. Andrews on 5/5/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 4, 2022 | 28 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for the parties to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 in accordance with the Court's oral order at the April 21, 2022 status conference to May 11, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Apr 28, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Tasneem A. Dharamsi and Robert L. Florence for Mylan Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Apr 22, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Christina Schwarz, Nicholas N. Kallas, and Jared L. Stringham for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Apr 22, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Christopher E. Loh for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Apr 20, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (D.I. 27 in 22-cv-451-RGA; D.I. 545 in 20-md-2930-RGA) MOTION for Pro Hac Vice Appearance of Attorney Robert L. Florence and Tasneem A. Dharamsi of Parker Poe Adams & Bernstein LLP, filed by Mylan Pharmaceuticals Inc.. Signed by Judge Richard G. Andrews on 4/20/2022. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-00451-RGA(nms) |
| Apr 20, 2022 | 27 | Motion for Leave to Appear Pro Hac Vice (4) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Robert L. Florence and Tasneem A. Dharamsi of Parker Poe Adams & Bernstein LLP - filed by Mylan Pharmaceuticals Inc.. (Moore, David) |
| Apr 19, 2022 | 26 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.s Initial Disclosures Pursuant To Rule 26(A)(1) And Paragraph 3 Of The Delaware Default Standard For Discovery filed by Mylan Pharmaceuticals Inc..(Moore, David) |
| Apr 14, 2022 | 25 | Statement (7) Docket Text: Answer re [15] Answer to Complaint, and Counterclaims, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 4/14/2022 (nms). |
| Apr 13, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) |
| Apr 13, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [24] MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, Jared L. Stringham, filed by Novartis Pharmaceuticals Corporation. Signed by Judge Richard G. Andrews on 4/13/2022. (nms) |
| Apr 7, 2022 | 22 | Notice of Appearance (1) Docket Text: NOTICE of Appearance by Daniel M. Silver on behalf of Novartis Pharmaceuticals Corporation (Silver, Daniel) |
| Apr 7, 2022 | 23 | Notice of Appearance (1) Docket Text: NOTICE of Appearance by Alexandra M. Joyce on behalf of Novartis Pharmaceuticals Corporation (Joyce, Alexandra) |
| Apr 7, 2022 | 24 | Main Document (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, Jared L. Stringham - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, Jared L. Stringham)(Joyce, Alexandra) |
| Apr 7, 2022 | 24 | Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, J (4) |
| Apr 5, 2022 | N/A | Case Transferred Out to Another District (0) Docket Text: Case transferred to District of Delaware re MDL 2930. Entire Case file electronically transmitted. (dk) [Transferred from West Virginia Northern on 4/5/2022.] |
| Apr 5, 2022 | N/A | Remark (0) Docket Text: Remark: MDL panel has been advised. (nmg) |
| Apr 5, 2022 | N/A | Remark (0) Docket Text: Remark: Related cases added per original civil cover sheet filed in the Northern District of West Virginia. (nmg) |
| Apr 5, 2022 | 19 | Order (2) Docket Text: CERTIFIED COPY OF JPML CONDITIONAL TRANSFER ORDER (CTO-1) re: pldg. ([82] in MDL No. 2930, 1 in WVN/1:21-cv-00146) transferring 1 action to the District of Delaware to be assigned to Honorable Richard G. Andrews. Inasmuch as no objection is pending at this time, the stay is lifted. Signed by Clerk of the Panel John W. Nichols on 4/5/2022. Associated Cases: MDL No. 2930, WVN/1:21-cv-00146. (dk) [Transferred from West Virginia Northern on 4/5/2022.] |
| Apr 5, 2022 | 20 | Main Document Public Docket Sheet (7) Docket Text: Record of case transferred in from District of West Virginia Northern; Case Number in Other District: 1:21-cv-00146. Copy of Docket Sheet and original file |
| Apr 5, 2022 | 20 | *Restricted* (7) |
| Apr 5, 2022 | 21 | Letter (2) Docket Text: Local Counsel Letter sent. Notice of Compliance deadline set for 5/5/2022. (mal) |
| Apr 1, 2022 | 17 | Stipulation and Order (3) Docket Text:STIPULATION AND ORDER dismissing Mylan, Inc., Mylan Laboratories Limited, and Viatris, Inc., without prejudice. Signed by Chief District Judge Thomas S Kleeh on 4/1/2022. (dk) [Transferred from West Virginia Northern on 4/5/2022.] |
| Apr 1, 2022 | 18 | Report of Rule 26(f) Planning Meeting (5) Docket Text: REPORT of Rule 26(f) Planning Meeting. (Copland, Gordon) [Transferred from West Virginia Northern on 4/5/2022.] |
| Mar 31, 2022 | 16 | Stipulation (4) Docket Text: STIPULATION and proposed order dismiss certain defendants by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Copland, Gordon) [Transferred from West Virginia Northern on 4/5/2022.] |
| Mar 24, 2022 | 14 | Disclosure Statement (3) Docket Text: Corporate Disclosure Statement by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc. identifying Corporate Parent Mylan Inc. for Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.; Corporate Parent Viatris Inc. for Mylan Inc... (Copland, Gordon) [Transferred from West Virginia Northern on 4/5/2022.] |
| Mar 24, 2022 | 15 | Answer to Complaint (22) Docket Text:Defendants' ANSWER to [1] Complaint and Mylan Pharaceuticals', COUNTERCLAIM agaubst Bivartus against Mylan Pharmaceuticals Inc. by Mylan Pharmaceuticals Inc., Viatris Inc., Mylan Laboratories Limited, Mylan Inc..(Copland, Gordon) [Transferred from West Virginia Northern on 4/5/2022.] |
| Feb 25, 2022 | 10 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE Returned Executed by Novartis Pharmaceuticals Corporation. Mylan Pharmaceuticals Inc. waiver sent on 2/16/2022, answer due 4/18/2022. (Companion, James) [Transferred from West Virginia Northern on 4/5/2022.] |
| Feb 25, 2022 | 11 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE Returned Executed by Novartis Pharmaceuticals Corporation. Mylan Inc. waiver sent on 2/16/2022, answer due 4/18/2022. (Companion, James) [Transferred from West Virginia Northern on 4/5/2022.] |
| Feb 25, 2022 | 12 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE Returned Executed by Novartis Pharmaceuticals Corporation. Mylan Laboratories Limited waiver sent on 2/16/2022, answer due 4/18/2022. (Companion, James) [Transferred from West Virginia Northern on 4/5/2022.] |
| Feb 25, 2022 | 13 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE Returned Executed by Novartis Pharmaceuticals Corporation. Viatris Inc. waiver sent on 2/16/2022, answer due 4/18/2022. (Companion, James) [Transferred from West Virginia Northern on 4/5/2022.] |
| Feb 22, 2022 | 9 | Order (5) Docket Text:FIRST ORDER AND NOTICE REGARDING DISCOVERY AND SCHEDULING: ***NOTICE TO ATTORNEYS*** : Pursuant to Rule 7.1 of the Federal Rules of Civil Procedure, ALL Non-governmental CORPORATE parties must file a DISCLOSURE STATEMENT with the Court. Forms are available on the Court's Web Site at http://www.wvnd.uscourts.gov/forms.htm Rule 26 Meeting to be held by 3/18/2022. Rule 26 Meeting Report due by 4/1/2022. Discovery due by 4/18/2022. Signed by District Judge Thomas S. Kleeh on 2/22/2022. (dk) [Transferred from West Virginia Northern on 4/5/2022.] |
| Feb 17, 2022 | 8 | Notice of Appearance (2) Docket Text: NOTICE of Appearance by Gordon H. Copland on behalf of Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc. (Copland, Gordon) [Transferred from West Virginia Northern on 4/5/2022.] |
| Jan 24, 2022 | 7 | Order Reassigning Case (1) Docket Text:ORDER. The Court ORDERS that the above-styled civil action be transferred to and placed on the docket of the Honorable Thomas S. Kleeh, District Judge. Senior Judge Irene M. Keeley no longer assigned to case. Signed by Senior Judge Irene M. Keeley on 1/24/2022. (dk) [Transferred from West Virginia Northern on 4/5/2022.] |
| Dec 20, 2021 | 1 | Main Document (14) Docket Text: COMPLAINT against All Defendants, filed by Novartis Pharmaceuticals Corporation. Filing Fee $402.00. Receipt No. AWVNDC-3393348. (Attachments: # (1) Exhibit A - U.S. Patent, # (2) Civil Cover Sheet) (dk)[Transferred from West Virginia Northern on 4/5/2022.] |
| Dec 20, 2021 | 1 | Exhibit A - U.S. Patent (16) |
| Dec 20, 2021 | 1 | Civil Cover Sheet (2) |
| Dec 20, 2021 | 2 | Notice of Appearance (1) Docket Text: VERIFICATION OF ATTORNEY ADMISSION re [1] Complaint to Nicholas Kallas, Christina Schwarz, Christopher Loh, and Jared Stringham. (dk) [Transferred from West Virginia Northern on 4/5/2022.] |
| Dec 20, 2021 | 3 | Patent/Trademark Report to Commissioner (2) Docket Text:PLAINTIFF'S RULE 7.1 DISCLOSURE STATEMENT Other Document filed by Novartis Pharmaceuticals Corporation. (Companion, James) [Transferred from West Virginia Northern on 4/5/2022.] |
| Dec 20, 2021 | 4 | ANDA Form (2) Docket Text:PLAINTIFF'S SUPPLEMENTAL ANDA Other Document filed by Novartis Pharmaceuticals Corporation. (Companion, James) [Transferred from West Virginia Northern on 4/5/2022.] |
| Dec 20, 2021 | 5 | Patent/Trademark Report to Commissioner (1) Docket Text:REPORT TO USPTO Other Document filed by Novartis Pharmaceuticals Corporation. (Companion, James) [Transferred from West Virginia Northern on 4/5/2022.] |
| Dec 20, 2021 | 6 | Patent/Trademark Report to Commissioner (1) Docket Text: REPORT to USPTO on the filing or determination of an action regarding re [1] Complaint. (dk) [Transferred from West Virginia Northern on 4/5/2022.] |
